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Severe malaria infection caused by Plasmodium falciparum is a global life-threatening disease and a leading cause of death
worldwide. Intensive investigations have demonstrated that macrophages play crucial roles in control of inﬂammatory and
immuneresponsesandclearanceofPlasmodium-falciparum-parasitizederythrocytes(PE).Thispaperfocusesonhowmacrophage
CD36 recognizes and internalizes PE and participates the inﬂammatory signaling in response to Plasmodium falciparum.I n
addition, recent advances in our current understanding of the biological actions of PPARγ on CD36 and malaria clearance from
the hosts are highlighted.
1.Introduction
Macrophages play a crucial role in the innate immunity
[1] and are essential components of defense against the
malaria infection. Macrophages can take up nonopsonic
or opsonic Plasmodium-falciparum-parasitized erythrocytes
(PE) by using CD36 and Fc receptors, respectively. Nonop-
sonic PE phagocytosis by macrophage CD36 plays a major
role for PE clearance especially in the acute phase of primary
malaria infection or nonimmune hosts [2, 3]. Therefore,
upregulation of CD36 on macrophages could greatly trigger
the capacity to clear parasites during acute malaria infection
a n dt h u si sl i k e l yt ob ee ﬀective treatment for malaria
infection. The intensive investigations demonstrate that
peroxisome proliferator-activator receptor γ (PPARγ)p l a y s
an important role in the immune response via inhibit-
ing the expression of inﬂammatory cytokines and control
macrophage alternative activation [4–6]a n dh a sp o t e n t i a l
as a novel anti-inﬂammatory target for many inﬂammatory
diseases [7] including parasitic infection [8–10]. CD36 can
be induced by PPARγ ligands, and activation of PPARγ
enhances the clearance of PE and inhibits the proinﬂamma-
tory response [6, 11]. Here, we highlight recent advances in
ourcurrentunderstandingofthebiologicalactionsofPPARγ
on CD36 and malaria clearance from the hosts.
2.CD36 andMalariaClearance
Macrophages play a crucial role in innate immunity to
malaria infection because they can phagocytose infected
erythrocytes that limit the malaria density in the absence
of cytophilic or opsonizing malaria-speciﬁc antibody [2].
Macrophage pattern-recognition receptors (PRRs), includ-
ing Toll-like receptors (TLRs) and scavenger receptors such
as CD36, are important components in the regulation of
immune and inﬂammatory responses [12]. PRRs are a
class of innate immune response-expressed proteins that
recognize a wide range of molecules known as pathogen-
associated molecular patterns (PAMPs) exposed on the
pathogensorpathogen-infectedcellsbutabsentfromhealthy
host cells and activate proinﬂammatory responses to infec-
tion. CD36, a member of the class B scavenger receptor
family, has been identiﬁed as a PRR [12]. CD36 is an 88-
kDa membrane glycoprotein that expressed on a wide range
of cells such as platelets, monocytes/macrophages, endothe-
lial cells, smooth muscle cells, and other types of cells.
CD36 expressed on macrophages is involved in recognition
and engulfment of endogenously derived ligands such as
apoptotic and senescent cells [13–16], thrombospondin-1
[17, 18], nonopsonized bacteria [19], β-amyloid [20], and
oxidized low-density lipoproteins (oxLDL) [21]. Because2 PPAR Research
CD36 is expressed by broad range of cells and involved in
uptake of many self- or non-self-particles, it contributes to
a varied list of physiological and pathologic processes such
as apoptotic cell clearance, angiogenesis, atherosclerosis,
Alzheimer’s disease and infectious diseases [22].
Macrophage CD36 is also involved in recognizing and
internalizing nonopsonized Plasmodium falciparum para-
sitized erythrocytes (PE) and help control replication of
blood-stage parasites, which is a critical component of
host defense mechanisms against blood-stage parasites [3,
23–28]. African populations contain high frequency of
mutations in CD36. These mutations that cause CD36
deﬁciency are associated with susceptibility to severe malaria
and cerebral malaria [29]. Nonopsonized PE by antibodies
or complements can be recognized and internalized by
macrophages via CD36 because Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1) expressed on
the surface of PE is the major parasite ligand for CD36
[2]. CD36 null mice show the importance of CD36 in PE
phagocytosis [2]. Macrophages from CD36 null mice or rat
lacking CD36 internalize signiﬁcantly fewer PE compared
to wild-type mice or control rats [2]. CD36-null mice
experience more severe and fatal malaria when challenged
with Plasmodium chabaudi chabaudi as compared with wild-
typemice[30].CD36-nullmicealsodisplaydefectinparasite
clearance,earlierpeakparasitemias,higherparasitedensities,
and higher mortality rates compared to wild-type mice [30].
These results suggest that selectively triggering of malaria
clearance by modulating CD36 expression may contribute to
control of acute blood-stage malaria infection in vivo.
Current data suggest that TLRs do not function directly
as phagocytic receptors [31]. Erdman et al. applied selective,
receptor-targeted strategies to show that macrophage pre-
treatment with TLR agonists markedly stimulates PE uptake
via CD36, suggesting that CD36 and TLRs cooperate func-
tionally to promote internalization of PE by macrophages
[27]. The TLR2 activation-enhanced phagocytosis capac-
ity for PE is unlikely via TLR-mediated transcription of
scavenger receptors because surface CD36 levels do not
increase upon TLR2 activation [27] .T h er o l eo fT L R 2f o r
the promotion of malaria clearance by macrophages may be
beneﬁcial in the control of acute blood stage parasite replica-
tion. Increasing understanding of the molecular mechanisms
involved may lead to development of strategies for manipu-
lating phagocyticclearanceofPlasmodiumfalciparumforthe
treatment malaria infection.
3. CD36 andInﬂammatoryResponses
Macrophage CD36 plays a very important role in the
physiological process including apoptotic cell clearance and
pathogenesis, of many diseases such as atherosclerosis,
Alzheimer’s disease and Plasmodium falciparum malaria
infection. In addition to clearance of altered self- or non-
self-components such as apoptotic cells, oxLDL, β-amyloid,
and pathogens, macrophage CD36 may be involved in
inﬂammatory signaling cascade by interacting with other
PRRs such as TLRs, which may further increase macrophage
phagocytosis capacity and dispose invaded pathogens or
trigger the chronic inﬂammation in these diseases. However,
the interaction between CD36 and TLRs is complex and
the consequences of the interaction are not fully under-
stood. Macrophage CD36 recognition and internalization of
apoptotic cells fails to stimulate proinﬂammatory response
from ingesting phagocytes but triggers an anti-inﬂammatory
response which is mediated by the release of interleukin
(IL)-10, transforming growth factor (TGF)-β [32, 33]a n d
inhibition of tumor necrosis factor-α (TNF-α), IL-12, IL-1β,
and IL-8 [33]. It was also demonstrated that macrophages
recognition and phagocytosis of late apoptotic cells does
not trigger the release of IL-8 and TNF-α. By contrast,
macrophages response to necrotic cells, including secon-
darily necrotic cells derived from uncleared apoptotic cells,
are perceived as proinﬂammatory [34]. Macrophage CD36-
dependent signaling is involved in the pro-inﬂammatory
eﬀects of internalizing β-amyloid, oxLDL, and bacteria [35–
37]. CD36 has been shown to cooperate with TLR2 in innate
sensingandinduceingofinﬂammatorycytokinesinresponse
to TLR2 agonists such as intact bacteria and bacterial ligands
[38–40]. By activation of src-family kinases, MAP kinases,
transcription factor nuclear factor κB( N F - κB), macrophage
CD36 recognition and internalization of oxLDL activates
pro-inﬂammatory signals such as release of cytokines and
production of reactive oxygen species (ROS) and inhibits
macrophage migration, which results in the formation
of foam cells and atherosclerotic plaque [12, 41]. For a
comprehensivereviewonCD36-inducedsignalingpathways,
see Moore and Freeman and Silverstein et al. [22, 41].
Microglia cell CD36 for β-amyloid uptake also boosts pro-
inﬂammatory response and may contribute to the patho-
genesis of Alzheimer’s disease [12]. CD36 recognition of
oxLDL and β-amyloid triggers assembly of a heterotrimeric
complex composed of CD36, TLR4 and TLR6, leading to
the induction of pro-inﬂammatory mediators implicated in
the deleterious eﬀects oxLDL and amyloid-β in vivo [42].
TLR2 also requires CD36 for inﬂammatory signaling [12].
CD36 is necessary for the component of ischemic brain
injury attributable to the inﬂammatory response triggered
by TLR2/1 activation [43]. The inﬂammatory response in
braininducedbyTLR2/1activation,butnotTLR2/6orTLR4
activation, is suppressed in CD36-null mice. In contrast
to brain inﬂammation, in systemic inﬂammation CD36 is
involved in TLR2/6 activation, but not TLR2/1 activation
[39, 40, 43]. This ﬁnding suggests that CD36 signaling in
neuroinﬂammation diﬀers from systemic inﬂammation; the
mechanism for such diﬀerences is unclear [43].
Macrophage CD36 also contributes to the induction
of innate immunity to malaria infection [30]. Macrophage
CD36 interaction with malaria and malaria products,
such as Plasmodium falciparum glycosylphosphatidylinosi-
tol (pfGPI), hemozoin and Plasmodium falciparum DNA,
known as pathogen-associated molecular patterns (PAMPs),
has been found to stimulate macrophage cytokine pro-
duction via collaboration with TLR family [44–46]. pfGPI
is the primary parasite-derived bioactive molecule that
activates macrophages and induces the release of inﬂamma-
tory cytokines such as TNF-α and IL-1 from macrophages
and, therefore, contributes to severe malarial pathogenesisPPAR Research 3
and morbidity [11, 47]. pfGPI interacts with macrophage
TLR2 by activation of JNK, P38, c-Jun and ERK1/2 in a
CD36-dependent manner [30, 48]. Hemozoin, also known
as malaria pigment, is insoluble crystal generated from
hemoglobin proteolysis by Plasmodium falciparum. Natural
hemozoin is coated with both proteins and plasmodial DNA
and a potent activator of the inﬂammatory response via
triggering TLR9 dependent on MyD88 [49, 50]. However,
some studies show that the inﬂammatory eﬀect of hemozoin
is dependent on the cells, duration of incubation time, and
the method for hemozoin preparation [51]. A recent study
demonstrated that a PAMP, AT-rich DNA in the genome of
Plasmodium falciparum, couples to stimulator of interferon
genes (STING) and TANK-binding kinase (TBK) to induce
interferon regulatory factor 3–7 (IRF3-IRF7) dependent on
type I IFN production in a TLR9-independent manner. Mice
lacking IRF3, IRF7, the kinase TBK1, or the type I IFN
receptor were resistant to lethal cerebral malaria [46]. This
study provides evidence of a unique DNA sensing pathway
that may contribute to immunopathology in plasmodial
infections [52].
T h er o l eo fC D 3 6i ni n ﬂ a m m a t o r ys i g n a l si nr e s p o n s e
to malaria infection remains controversial. Several lines of
evidence suggest that selective ligation of CD36 does not lead
to proinﬂammatory cytokine production by macrophages
[3, 28]. Erdman et al. applied selective, receptor-targeted
strategies to assess whether CD36 and TLRs can coopera-
tively mediate immune response to PE. They demonstrate
that targeted activation and internalization of CD36 fail to
stimulateproinﬂammatorycytokineproduction[27].CD36-
mediated intact PE internalization is also noninﬂammatory
even in the presence of TLR agonists [27]. These data
suggest that it is possible that CD36 is not directly involved
in regulation of pro-inﬂammatory response to Plasmodium
falciparum but rather presents or concentrates ligands for
recognition by other signaling receptors such as TLRs [30],
similar to the role of CD14 in presenting or concentrating
LPS signal to TLR4 [53]. Taken together, the contradictory
data about CD36 on inﬂammatory response to parasite and
parasite produce indicate that further investigation is needed
for the role of CD36 in parasitic infection.
4. PPARγ Ligand
PPARs are nuclear receptors which are ligand-activated
transcription factors. To date, three diﬀerent PPAR sub-
t y p e sh a v eb e e ni d e n t i ﬁ e dP P A R α,P P A R β/δ,a n dP P A R γ.
PPARγ was ﬁrst identiﬁed for its role in lipid and glucose
metabolism. PPARγ is critical in a variety of biological
processes. Natural and synthetic ligands bind to PPARγ,
resulting in conformational change and activation of PPARγ.
Natural Ligands. Prostaglandin 15-deoxy-Δ12,14-prostagl-
andin J2 (15d-PGJ2) was the ﬁrst discovered endogenous
ligand for PPARγ [54, 55]. 15d-PGJ2 is a potent activator
for PPARγ and responsible for many of anti-inﬂammato-
ry actions [56]. The variety lipophilic ligands can bind and
activate PPARγ. The essential fatty acids, arachidonic acid,
gamolenic acid, docosahexanoic acid, eicosapentaenoic acid,
and components of oxLDL, such as 9,13-hydroxyoctadecadi-
enoic acid (HODE) and 8,15-hydroxyeicosatetraenoic acid
(HETE) are also potent endogenous activators of PPARγ
[57]. These PPARγ ligands can be regulated by lipoxygenase
and cytokines. For example, 13-HODE and 15-HETE can be
generated from linoleic and arachidonic acids, respectively,
by a 12/15-lipoxygenase that is upregulated by interleukin-
4[ 5, 58]. Plasmodium falciparum may itself activate PPARγ.
Plasmodium falciparum produces hemozoin, which induces
thereleaseoflipoxinA4 (LXA4),5,15-diHETE,and15-HETE
that can activate PPAR [59].
Synthetic PPARγ Ligands. In addition to natural ligands,
many synthetic ligands have been identiﬁed. The anti-
diabetic drugs thiazolidinediones (TZDs) including trogli-
tazone, rosiglitazone, pioglitazone, and ciglitazone, used
for the treatment of type 2 diabetes, are synthetic PPARγ
agonists [7, 60]. They regulate the expression of genes that
are involved in lipid metabolism and insulin action by acti-
vation of PPARγ. Furthermore, TZDs have beneﬁcial anti-
inﬂammatory properties that are widely used for treatment
of patients with inﬂammatory diseases [7].
5. PPARγ andCD36
Macrophage and macrophage CD36 play a critical role in
clearing PE and protecting host from high density of para-
sites during acute blood-stage malaria infection [28, 30, 61].
Therefore,upregulationofCD36expressiononmacrophages
may trigger parasite clearance and enhance survival of the
host. CD36 can be upregulated by diﬀerent molecules. Treat-
ment macrophages with oxLDL and inﬂammatory cytokines
such as granulocyte macrophage colony-stimulating factor
(GM-CSF), macrophage colony-stimulating factor(M-CSF),
upregulate CD36 expression [62]. The mechanism of induc-
tion of CD36 by oxLDL and these cytokines is due to the
ability to activate PPARγ [63]. In addition, both IL-13 and
IL-4, which induce an alternative activation of macrophages
[64], induce expression of CD36 by generation of natural
ligands of PPARγ [5, 65]. The functional consequences of
CD36 expression and PPARγ activation induced by IL-13 are
to enhance phagocytosis of PE [65] .T h er o l eo fP P A R γ in
CD36 expression is further conﬁrmed by using macrophages
lacking expression of PPARγ. By using macrophages diﬀer-
entiated from PPARγ-deﬁcient embryonic stem cells, PPARγ
is not essential for macrophage diﬀerentiation, but it is
required for basal expression of CD36 [66] and necessary
for the regulation of CD36 in response to PPARγ ligands
in PPARγ-deﬁcient stem cell-diﬀerentiated macrophages
[67]. IL-13 up-regulates macrophage CD36 expression, and
it is ineﬀective on CD36 induction on PPARγ-deﬁcient
macrophages compared to wild-type cells [65]. It is particu-
larly interesting because IL-13 not only induces macrophage
alternative activation [64] which could help control parasite
burden while limiting associated inﬂammation and thus
reducinghostpathology,butalsoenhancesCD36-dependent
PE phagocytosis without TLR2 involvement [65].4 PPAR Research
Incubation of macrophages with PPAR-RXR agonists,
including 15d-PGJ2, 9-cis-retinoic acid (9-cis-RA), and TZD
increase CD36 expression on macrophages which associates
with increased capacity for phagocytosis of PE [28]. This
increase in phagocytosis of PE is accompanied by a decrease
in parasite-induced TNF-α production. PPARγ agonist
rosiglitazone enhances phagocytic clearance of PE and
inhibitsinﬂammatoryresponsestoinfectionviainhibitionof
pfGPI-induced activation of the MAPK and NF-κB signaling
pathways [8]. Furthermore, rosiglitazone reduces the para-
sitemia in a CD36-dependent manner in the Plasmodium
chabaudi chabaudi hyperparasitemia model and improves
the survival rate even when treatment is initiated as late as
day 5 after infection [8]. These results indicate that speciﬁc
upregulation of CD36 by these compounds may represent
a novel means for modulating host clearance of PE and
proinﬂammatory responses to Plasmodium falciparum [28].
Despite studies about PPARγ agonists that enhance CD36
expressionanduptakePE,thistreatmentraisesconcernsthat
treating individual with PPARγ agonists could also enhance
CD36 expression on endothelial cells and thus triggers the
adherence of PE to endothelial cells in various blood vessels.
Therefore, speciﬁc upregulation of CD36 expression on
macrophages may represent a novel therapeutic strategy to
treat malaria infections.
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